Objective-It is known that both platelets and coagulation strongly influence infarct progression after ischemic stroke, but the mechanisms and their interplay are unknown. Our aim was to assess the contribution of the procoagulant platelet surface, and thus platelet-driven thrombin generation, to the progression of thromboinflammation in the ischemic brain. Approach and Results-We present the characterization of a novel platelet and megakaryocyte-specific TMEM16F (anoctamin 6) knockout mouse. Reflecting Scott syndrome, platelets from the knockout mouse had a significant reduction in procoagulant characteristics that altered thrombin and fibrin generation kinetics. In addition, knockout mice showed significant defects in hemostasis and arterial thrombus formation. However, infarct volumes in a model of ischemic stroke were comparable with wild-type mice. Conclusions-Platelet TMEM16F activity contributes significantly to hemostasis and thrombosis but not cerebral thromboinflammation. These results highlight another key difference between the roles of platelets and coagulation in these processes.
D uring the process of thrombus formation, platelets interact with the coagulation system, providing a so-called procoagulant surface that facilitates thrombin generation. The major component of this procoagulant platelet surface is negatively charged aminophospholipids, which are exposed after platelet activation and sustained Ca 2+ signaling. These lipids serve as anchoring sites for vitamin K-dependent coagulation factors, thus supporting the assembly of the tenase and prothrombinase complexes, which jointly enhance the rate of thrombin generation by 5 to 10 orders of magnitude. 1 In addition to aminophospholipid exposure, procoagulant platelets also dramatically increase their size through a regulated process termed membrane ballooning 2 or swelling, 3 which increases the membrane surface area for coagulation factor binding. The importance of this procoagulant surface for the crosstalk between platelet activation and coagulation is beginning to be more fully understood through the analysis of patients who have the rare bleeding disorder Scott syndrome. 1, 4 This disorder, characterized by incidences of provoked bleeding and a decrease in prothrombin consumption measurements, has been attributed to mutations in the gene encoding the Ca 2+ -activated channel and scramblase TMEM16F (anoctamin 6). 5, 6 The primary defects in the platelets from the 3 known Scott syndrome patients are significant decreases in Ca 2+ -induced phosphatidylserine exposure, as well as microparticle formation, and diminished platelet membrane ballooning after activation highlighting TMEM16F as a potential key regulator of the procoagulant platelet surface. 7 It is known that both platelets and coagulation strongly influence infarct progression after ischemic stroke. [8] [9] [10] Our aim was to assess the contribution of the procoagulant platelet surface, and thus platelet-driven thrombin generation, to the progression of thromboinflammation in the ischemic brain using a newly generated TMEM16F knockout mouse model.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
TMEM16F expression in platelets and megakaryocytes was abolished by targeted deletion of exon 3, which affected all splice variants of the Ano6 gene. 11, 12 Reverse transcription polymerase chain reaction using platelet mRNA from TMEM16F knockout mice (Ano6 fl/flPf4Cre , conditional knockout [cKO]) showed a complete absence of the exon 3 coded region at the mRNA level ( Figure 1Ai ). This strategy resulted in abolished protein expression as demonstrated by the Western blotting of wild-type (WT) and cKO platelet lysates ( Figure  1Aii ). Platelet count and size were not significantly different between cKO and WT mice and no alterations, either in the surface expression of the major platelet glycoproteins or in coagulation parameters prothrombin time and activated partial thromboplastin time were observed (Tables I and II in the online-only Data Supplement). Also, cKO platelets were not significantly different from WT in terms of integrin activation and P-selectin exposure after stimulation with agonists that activate the major platelet signaling pathways ( Figure IIA and IIB in the online-only Data Supplement) and also showed no activation defects in aggregometry studies ( Figure IIC in the online-only Data Supplement).
However, after stimulation with a combination of collagen-related peptide and thrombin (to costimulate both GPCR [G-protein-coupled receptor] and ITAM [immunoreceptor tyrosine-based activation motif]-coupled signaling pathways) or the calcium ionophore, ionomycin, significantly less cKO platelets exposed phosphatidylserine than WT (as measured by Annexin A5 binding in flow cytometry). The cKO platelets that did expose phosphatidylserine bound less Annexin A5, which resulted in the appearance of an intermediate population described as low Annexin A5 binding ( Figure 1D and 1E; Figure III in the online-only Data Supplement). Importantly, the differences observed in phosphatidylserine exposure were not because of differential activation of platelets as WT and cKO platelets showed comparable degranulation when costimulated with collagen-related peptide/thrombin or ionomycin ( Figure III in the online-only Data Supplement). Platelet membrane ballooning (observed as an increase in light transmission after ionomycin stimulation of nonaggregating platelets or within platelet aggregates formed on a collagen and tissue factor microspot under flow) was also severely impaired in cKO platelets ( Figure 1F and 1G). These in vitro and ex vivo data confirmed that the generated TMEM16F cKO mice had reduced platelet procoagulant potential. This is in line with observations of platelets from patients with Scott syndrome and other recently published TMEM16F knockout mouse models. 11, 13, 14 Given the reductions in procoagulant transformation, we assessed the ability of cKO platelets to promote thrombin generation. Measurement of thrombin generation over time using WT and cKO platelet-rich plasma revealed that the in vitro defects observed in cKO platelets led to significantly decelerated, but not abolished, thrombin generation. In all conditions tested, the time to initiation of thrombin generation (lagtime) and the time taken to reach peak thrombin concentrations were significantly delayed in cKO samples. Also, the peak thrombin concentrations reached were significantly lower in cKO samples than in WT samples (Figure 2A and 2B ). This significant alteration in thrombin generation kinetics did not lead to a reduction in the integrated amount of thrombin produced, with endogenous thrombin potential values comparable between WT and cKO ( Figure IV in the online-only Data Supplement). The delay in thrombin generation in cKO platelet-rich plasma translated into significantly delayed fibrin generation in an ex vivo whole-blood flow chamber model, with many samples not supporting fibrin generation within the observation window ( Figure 2C) .
To evaluate the consequence of the reduced procoagulant potential of cKO platelets for hemostasis, cKO mice were challenged in a tail bleeding assay and were found to have markedly prolonged bleeding times compared with WT mice ( Figure 2D ). Furthermore, when cKO mice were subjected to an FeCl 3 injury in the carotid artery to assess thrombosis, ≈50% did not form a stable occlusion within the observation period and the remaining cKO animals formed a stable vessel occlusion significantly later than WT mice. This result closely reflected the results of the ex vivo fibrin generation assay in Figure 1C . In the thrombosis model, the defects in the cKO mice appeared to be because of frequent incidences of embolization ( Figure 2E ; Figure V in the online-only Data Supplement). This clear influence of platelet TMEM16F function on hemostasis and thrombosis was not the case for thromboinflammatory processes. In the transient middle cerebral artery occlusion model of ischemic stroke, cKO mice had similar brain infarct volumes ( Figure 2F ), neurological outcomes (tested by the Bederson score, Figure 2G ) and motor function, and coordination outcomes (tested by the grip test, Figure 2H ) as WT mice.
Discussion
It has been recently shown that 2 parameters are of relevance in determining the contribution that platelets make to thrombin generation and, thus, coagulation. Not only is the ability of platelets to present negatively charged phosphatidylserine on their surface important but also their capacity to increase the surface area over which phosphatidylserine is presented, by controlled membrane ballooning/swelling. 2 As observed in patients with Scott syndrome, platelets from cKO mice had a severe reduction in both procoagulant characteristics. 11 However, residual phosphatidylserine exposure remained, with some agonists stimulating more phosphatidylserine exposure in cKO platelets than others, suggesting that the activity of TMEM16F is not the only mechanism behind membrane phospholipid scrambling after platelet activation. These observations have been previously made in Scott syndrome platelets and also in platelets of constitutive TMEM16F knockout mice. The mechanism behind the residual phosphatidylserine exposure and the differential effects of ionophores and other agonists on its levels remains incompletely understood. 11, 13, 15 However, a growing body of evidence suggests that the level of intracellular Ca 2+ mobilized strongly influences the bifurcation between TMEM16F-dependent and TMEM16F-independent phosphatidylserine exposure pathways. 15, 16 Despite the fragments were used to block αIIbβ3 integrins, and thus aggregation. Although WT platelets showed a rapid increase in light transmission, associated with a change to a ballooned morphology, cKO platelets did not. G, Count of platelets with ballooned membranes, formed on collagen/tissue factor microspots under flow. Alexa Fluor 568 Annexin A5 labeled, citrated whole blood was perfused over a collagen/tissue factor microspot for 4.5 min to allow aggregate formation and the number of ballooned platelets in the field of view were counted (number of ballooned platelets/image±SD, n=10) with representative images from WT and cKO samples (scale bar, 2 µm) *P<0.05, **P<0.01, ***P<0.001; unpaired Student t test.
Figure 2.
TMEM16F-mediated acceleration of thrombin generation is important for hemostasis, thrombosis and infarct growth in the ischemic brain. A, Quantification of tissue factor initiated thrombin generation measurements at 37°C. Conditional knockout (cKO) samples showed significantly increased time to initiation of thrombin generation (lagtime, left), time taken to reach peak thrombin (Continued) residual phosphatidylserine exposure in cKO platelets, the kinetics of thrombin generation were significantly altered in thrombin generation assays, which translated into defects in ex vivo fibrin generation, thrombosis, and hemostasis. This confirmed the importance of platelet TMEM16F function for thrombus formation, despite a recent publication implicating a greater role for the procoagulant endothelium using a laser injury model. 17 Importantly, our data indicate that this influence of platelet TMEM16F is not because of a reduction in the overall levels of thrombin generated over a prolonged period, as previously reported, but rather because the rate at which it is produced, a factor on which classical thrombosis appears to be critically dependent. 13, 14 Unexpectedly, this does not seem to be the case for thromboinflammation, as the absence of platelet TMEM16F did not affect infarct progression or functional outcomes post ischemic stroke, despite the clear relevance of thrombin and coagulation in this setting. 8, 18, 19 The overall difference between the loss of platelet TMEM16F on thrombosis and thromboinflammation may reflect the different timescales over which these processes occur. As infarct development and progression occurs over hours and thrombosis over minutes, the altered kinetics of cKO platelet-driven thrombin generation may not be relevant to the thromboinflammatory process. Furthermore, over longer time periods, other cell types such as red blood cells, activated endothelium, lymphocytes, and neurons are also known to become procoagulant, and so could contribute to thrombin levels within infarcted brain tissue. [20] [21] [22] [23] These data suggest that TMEM16F is not the sole mediator of agonist-induced phosphatidylserine exposure. However, its activity is critical for the acceleration of this response and, thus, platelet-driven thrombin formation. This modulation of thrombin generation kinetics by TMEM16F in platelets is critical for hemostasis and thrombosis, but not during thromboinflammation reflecting the different roles of platelets and coagulation in these processes.
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Continued. levels (time to peak, middle) and significantly reduced peak thrombin concentrations (thrombin, right). Mean±SD, *P<0.05, **P<0.01, ***P<0.001; unpaired Student t test. B, Representative calibrated automated thrombogram (CAT) curves. i, Platelet-rich plasma (PRP). ii, Collagen-related peptide (CRP)/P (PRP costimulated with 20 µg/mL CRP and 5 mmol/L PAR-4 peptide). iii, A23187 (PRP stimulated with 10 µmol/L A23187). C, TMEM16F cKO samples show significantly delayed fibrin formation under flow. Citrated whole blood prelabeled with DiOC 6 to mark platelets and Alexa Fluor 647 fibrinogen to detect fibrin(ogen) was perfused over a collagen/tissue factor microspot at 1000 s −1 until fibrin formation was observed (**P<0.01; unpaired Student t test) or for a total of 8 min (*P<0.05; Fisher exact test). D, TMEM16F cKO mice have significantly prolonged tail bleeding times. ***P<0.001; Fisher exact test. E, TMEM16F cKO mice are significantly protected from FeCl 3 -induced thrombosis in the carotid artery. Fifty percent of the cKO mice did not form an occlusive thrombus within the observation period (*P<0.05; Fisher exact test) and the rest showed significant prolongation of mean time to occlusion (wild-type [WT]=8.8±2.2 min; cKO=15.3±3.9 min; *P<0.05; unpaired Student t test). F, Twenty-four hours after 60-min ischemic injury TMEM16F cKO mice have infarct size and functional outcomes comparable to WT mice. Representative images (left) and quantification of infarct volume in 2,3,5-triphenyl-2H-tetrazolium chloride-stained brain sections (right; mean±SD). G, Bederson score, for analysis of global neurological defects (0 normal, 5 worst deficit); and H, Grip test, for analysis of motor function and coordination deficits (5 normal, 0 worst deficit).
